Allan Bradley active positions
| Companies | Position | Start | End |
|---|---|---|---|
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 31/12/2009 | - |
| Chief Tech/Sci/R&D Officer | 31/12/2009 | - | |
| Founder | 31/12/2009 | - | |
| Corporate Officer/Principal | 15/07/2010 | 15/07/2010 | |
PetMedix Ltd.
 PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 31/12/2017 | - |
| Chief Tech/Sci/R&D Officer | 31/12/2017 | - | |
| Founder | 31/12/2017 | - | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 05/10/2016 | - |
Career history of Allan Bradley
Former positions of Allan Bradley
| Companies | Position | Start | End |
|---|---|---|---|
Wellcome Trust Sanger Institute
 Wellcome Trust Sanger Institute BiotechnologyHealth Technology Wellcome Trust Sanger Institute provides genomic research services. It also provides research in the areas of cancer, agaeing, somatic mutation, cellular genetics, human genetics, infection genomics, and malaria. The company was founded in October 1993 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 31/12/1999 | 31/12/2009 |
Training of Allan Bradley
| University of Cambridge | Doctorate Degree |
Statistics
International
| United Kingdom | 6 |
Operational
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Wellcome Trust Sanger Institute
Wellcome Trust Sanger Institute BiotechnologyHealth Technology Wellcome Trust Sanger Institute provides genomic research services. It also provides research in the areas of cancer, agaeing, somatic mutation, cellular genetics, human genetics, infection genomics, and malaria. The company was founded in October 1993 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
- Stock Market
- Insiders
- Allan Bradley
- Experience
